// Immunology/Rheumatology - Drugs
// Auto-generated from modularize-data.js

const drugs = [

    {
        "id": "sulfasalazine",
        "name": "Sulfasalazine",
        "pharmacologicClass": "disease-modifying-antirheumatic-drugs-dmards",
        "therapeuticClass": "immunosuppressants",
        "system": "immunology-rheumatology",
        "mechanism": "Various mechanisms to suppress immune system and slow disease progression.",
        "features": "Anti-inflammatory and immunosuppressive.",
        "clinicalChoice": "RA, inflammatory bowel disease.",
        "indications": [
            "Rheumatoid Arthritis",
            "Ulcerative Colitis"
        ],
        "contraindications": [
            "Sulfonamide Allergy",
            "G6PD Deficiency"
        ],
        "sideEffects": [
            "Immunosuppression",
            "Hepatotoxicity",
            "Myelosuppression"
        ],
        "interactions": "Live vaccines contraindicated, increased infection risk.",
        "interactionDetails": "LIVE VACCINES: MECHANISM - DMARDs suppress immune system function, reducing ability to mount adequate immune response. CONSEQUENCE - Risk of disseminated infection from live vaccines, potentially fatal. Use killed vaccines only.",
        "pageType": "drug"
    },
    {
        "id": "adalimumab",
        "name": "Adalimumab",
        "pharmacologicClass": "biologic-dmards",
        "therapeuticClass": "immunosuppressants",
        "system": "immunology-rheumatology",
        "mechanism": "Target specific inflammatory mediators (TNF-α, IL-1, IL-6).",
        "features": "TNF-α inhibitor, subcutaneous injection.",
        "clinicalChoice": "RA, psoriatic arthritis, IBD.",
        "indications": [
            "Rheumatoid Arthritis",
            "Psoriatic Arthritis",
            "Crohn Disease"
        ],
        "contraindications": [
            "Active Infection",
            "Latent TB"
        ],
        "sideEffects": [
            "Increased infection risk",
            "Injection site reactions",
            "Reactivation of TB"
        ],
        "interactions": "Live vaccines, other immunosuppressants.",
        "interactionDetails": "OTHER IMMUNOSUPPRESSANTS: MECHANISM - Additive immunosuppressive effects when combined with conventional DMARDs or corticosteroids. CONSEQUENCE - Significantly increased risk of opportunistic infections including PCP, TB reactivation, and fungal infections.",
        "pageType": "drug"
    },
    {
        "id": "etanercept",
        "name": "Etanercept",
        "pharmacologicClass": "biologic-dmards",
        "therapeuticClass": "immunosuppressants",
        "system": "immunology-rheumatology",
        "mechanism": "Target specific inflammatory mediators (TNF-α, IL-1, IL-6).",
        "features": "TNF receptor fusion protein.",
        "clinicalChoice": "Rheumatoid arthritis refractory to methotrexate.",
        "indications": [
            "Rheumatoid Arthritis",
            "Psoriatic Arthritis"
        ],
        "contraindications": [
            "Active Infection",
            "Latent TB"
        ],
        "sideEffects": [
            "Increased infection risk",
            "Injection site reactions",
            "Reactivation of TB"
        ],
        "interactions": "Live vaccines, other immunosuppressants.",
        "interactionDetails": "OTHER IMMUNOSUPPRESSANTS: MECHANISM - Additive immunosuppressive effects when combined with conventional DMARDs or corticosteroids. CONSEQUENCE - Significantly increased risk of opportunistic infections including PCP, TB reactivation, and fungal infections.",
        "pageType": "drug"
    },
    {
        "id": "rituximab",
        "name": "Rituximab",
        "pharmacologicClass": "biologic-dmards",
        "therapeuticClass": "immunosuppressants",
        "system": "immunology-rheumatology",
        "mechanism": "Target specific inflammatory mediators (TNF-α, IL-1, IL-6).",
        "features": "Anti-CD20, depletes B cells.",
        "clinicalChoice": "RA refractory to TNF inhibitors.",
        "indications": [
            "Rheumatoid Arthritis",
            "Non-Hodgkin Lymphoma"
        ],
        "contraindications": [
            "Active Infection",
            "Severe Heart Failure"
        ],
        "sideEffects": [
            "Increased infection risk",
            "Injection site reactions",
            "Reactivation of TB"
        ],
        "interactions": "Live vaccines, other immunosuppressants.",
        "interactionDetails": "OTHER IMMUNOSUPPRESSANTS: MECHANISM - Additive immunosuppressive effects when combined with conventional DMARDs or corticosteroids. CONSEQUENCE - Significantly increased risk of opportunistic infections including PCP, TB reactivation, and fungal infections.",
        "pageType": "drug"
    },
    {
        "id": "cyclosporine",
        "name": "Cyclosporine",
        "pharmacologicClass": "calcineurin-inhibitors",
        "therapeuticClass": "immunosuppressants",
        "system": "immunology-rheumatology",
        "mechanism": "Inhibit calcineurin to block IL-2 transcription and T-cell activation.",
        "features": "Binds cyclophilin.",
        "clinicalChoice": "Transplant rejection prophylaxis, severe psoriasis.",
        "indications": [
            "Organ Transplantation",
            "Psoriasis"
        ],
        "contraindications": [
            "Uncontrolled Hypertension",
            "Renal Dysfunction"
        ],
        "sideEffects": [
            "Nephrotoxicity",
            "Hypertension",
            "Neurotoxicity",
            "Gingival hyperplasia (cyclosporine)"
        ],
        "interactions": "CYP3A4 inhibitors markedly increase levels.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "tacrolimus",
        "name": "Tacrolimus",
        "pharmacologicClass": "calcineurin-inhibitors",
        "therapeuticClass": "immunosuppressants",
        "system": "immunology-rheumatology",
        "mechanism": "Inhibit calcineurin to block IL-2 transcription and T-cell activation.",
        "features": "Binds FKBP-12, more potent.",
        "clinicalChoice": "Solid organ transplant prophylaxis.",
        "indications": [
            "Organ Transplantation"
        ],
        "contraindications": [
            "Severe Renal Impairment"
        ],
        "sideEffects": [
            "Nephrotoxicity",
            "Hypertension",
            "Neurotoxicity",
            "Gingival hyperplasia (cyclosporine)"
        ],
        "interactions": "CYP3A4 inhibitors markedly increase levels.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "mycophenolate-mofetil",
        "name": "Mycophenolate Mofetil",
        "pharmacologicClass": "antimetabolite-immunosuppressants",
        "therapeuticClass": "immunosuppressants",
        "system": "immunology-rheumatology",
        "mechanism": "Inhibit nucleotide synthesis to prevent lymphocyte proliferation.",
        "features": "Inhibits IMP dehydrogenase in lymphocytes.",
        "clinicalChoice": "Transplant rejection prophylaxis, lupus nephritis.",
        "indications": [
            "Organ Transplantation",
            "Lupus Nephritis"
        ],
        "contraindications": [
            "Pregnancy"
        ],
        "sideEffects": [
            "Myelosuppression",
            "GI upset",
            "Hepatotoxicity"
        ],
        "interactions": "Allopurinol increases azathioprine toxicity; antacids reduce mycophenolate absorption.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "azathioprine",
        "name": "Azathioprine",
        "pharmacologicClass": "antimetabolite-immunosuppressants",
        "therapeuticClass": "immunosuppressants",
        "system": "immunology-rheumatology",
        "mechanism": "Inhibit nucleotide synthesis to prevent lymphocyte proliferation.",
        "features": "Prodrug of 6-mercaptopurine.",
        "clinicalChoice": "Steroid-sparing agent for autoimmune disease.",
        "indications": [
            "Rheumatoid Arthritis",
            "Inflammatory Bowel Disease"
        ],
        "contraindications": [
            "Thiopurine Methyltransferase Deficiency"
        ],
        "sideEffects": [
            "Myelosuppression",
            "GI upset",
            "Hepatotoxicity"
        ],
        "interactions": "Allopurinol increases azathioprine toxicity; antacids reduce mycophenolate absorption.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "sirolimus-rapamycin",
        "name": "Sirolimus (Rapamycin)",
        "pharmacologicClass": "mtor-inhibitors",
        "therapeuticClass": "immunosuppressants",
        "system": "immunology-rheumatology",
        "mechanism": "Block mTOR signaling downstream of IL-2 to prevent T-cell proliferation.",
        "features": "Used with calcineurin inhibitors to prevent chronic rejection.",
        "clinicalChoice": "Renal transplant immunosuppression.",
        "indications": [
            "Renal Transplantation"
        ],
        "contraindications": [
            "Severe Hepatic Impairment"
        ],
        "sideEffects": [
            "Hyperlipidemia",
            "Bone marrow suppression",
            "Mouth ulcers"
        ],
        "interactions": "CYP3A4 and P-gp substrates.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "methylprednisolone",
        "name": "Methylprednisolone",
        "pharmacologicClass": "systemic-corticosteroids",
        "therapeuticClass": "corticosteroids",
        "system": "immunology-rheumatology",
        "mechanism": "Bind glucocorticoid receptors, suppress inflammatory gene transcription.",
        "features": "IV/PO, more potent than prednisone.",
        "clinicalChoice": "Acute inflammatory conditions.",
        "indications": [
            "Severe Asthma",
            "Acute MS Relapse"
        ],
        "contraindications": [
            "Systemic Fungal Infections"
        ],
        "sideEffects": [
            "Osteoporosis",
            "Diabetes",
            "Infection risk",
            "Adrenal suppression"
        ],
        "interactions": "CYP3A4 inducers reduce efficacy, live vaccines.",
        "interactionDetails": "CYP3A4 INDUCERS: MECHANISM - Rifampin, phenytoin increase cortisol metabolism, reducing therapeutic levels. CONSEQUENCE - Loss of anti-inflammatory efficacy, potential disease flare. May need dose adjustment.",
        "pageType": "drug"
    },
    {
        "id": "allopurinol",
        "name": "Allopurinol",
        "pharmacologicClass": "uric-acid-lowering-agents",
        "therapeuticClass": "gout-medications",
        "system": "immunology-rheumatology",
        "mechanism": "Reduce uric acid production (allopurinol) or increase excretion (probenecid).",
        "features": "Xanthine oxidase inhibitor.",
        "clinicalChoice": "Chronic gout prevention, tumor lysis syndrome.",
        "indications": [
            "Chronic Gout",
            "Hyperuricemia",
            "Tumor Lysis Syndrome"
        ],
        "contraindications": [
            "Acute Gout Attack",
            "HLA-B*5801 (Asians)"
        ],
        "sideEffects": [
            "Gout flares initially",
            "Hypersensitivity reactions",
            "Kidney stones"
        ],
        "interactions": "Azathioprine with allopurinol (severe toxicity).",
        "interactionDetails": "AZATHIOPRINE: MECHANISM - Allopurinol inhibits xanthine oxidase, which metabolizes azathioprine. This leads to accumulation of toxic metabolites. CONSEQUENCE - Severe myelosuppression and life-threatening bone marrow toxicity requiring dose reduction.",
        "pageType": "drug"
    },
    {
        "id": "probenecid",
        "name": "Probenecid",
        "pharmacologicClass": "uric-acid-lowering-agents",
        "therapeuticClass": "gout-medications",
        "system": "immunology-rheumatology",
        "mechanism": "Reduce uric acid production (allopurinol) or increase excretion (probenecid).",
        "features": "Uricosuric agent, blocks renal reabsorption.",
        "clinicalChoice": "Gout in patients with normal kidney function.",
        "indications": [
            "Chronic Gout"
        ],
        "contraindications": [
            "Kidney Stones",
            "Severe Renal Impairment"
        ],
        "sideEffects": [
            "Gout flares initially",
            "Hypersensitivity reactions",
            "Kidney stones"
        ],
        "interactions": "Azathioprine with allopurinol (severe toxicity).",
        "interactionDetails": "AZATHIOPRINE: MECHANISM - Allopurinol inhibits xanthine oxidase, which metabolizes azathioprine. This leads to accumulation of toxic metabolites. CONSEQUENCE - Severe myelosuppression and life-threatening bone marrow toxicity requiring dose reduction.",
        "pageType": "drug"
    },
    {
        "id": "colchicine",
        "name": "Colchicine",
        "pharmacologicClass": "acute-gout-treatment",
        "therapeuticClass": "gout-medications",
        "system": "immunology-rheumatology",
        "mechanism": "Anti-inflammatory effects to treat acute gout attacks.",
        "features": "Microtubule inhibitor, anti-inflammatory.",
        "clinicalChoice": "Acute gout attacks, familial Mediterranean fever.",
        "indications": [
            "Acute Gout",
            "Familial Mediterranean Fever"
        ],
        "contraindications": [
            "Severe Renal/Hepatic Impairment"
        ],
        "sideEffects": [
            "GI upset",
            "Diarrhea",
            "Neutropenia"
        ],
        "interactions": "CYP3A4 inhibitors increase colchicine toxicity.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "indomethacin",
        "name": "Indomethacin",
        "pharmacologicClass": "acute-gout-treatment",
        "therapeuticClass": "gout-medications",
        "system": "immunology-rheumatology",
        "mechanism": "Anti-inflammatory effects to treat acute gout attacks.",
        "features": "Potent NSAID.",
        "clinicalChoice": "Acute gout when colchicine contraindicated.",
        "indications": [
            "Acute Gout",
            "Patent Ductus Arteriosus"
        ],
        "contraindications": [
            "Peptic Ulcer Disease",
            "Severe Heart Failure"
        ],
        "sideEffects": [
            "GI upset",
            "Diarrhea",
            "Neutropenia"
        ],
        "interactions": "CYP3A4 inhibitors increase colchicine toxicity.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "tofacitinib",
        "name": "Tofacitinib",
        "pharmacologicClass": "jak-inhibitors",
        "therapeuticClass": "rheumatoid-arthritis-medications",
        "system": "immunology-rheumatology",
        "mechanism": "Oral JAK inhibitor (JAK1/JAK3) that blocks cytokine signaling pathways involved in inflammation and immune response.",
        "features": "First oral JAK inhibitor for RA, small molecule (not biologic), rapid onset.",
        "clinicalChoice": "Moderate-severe RA refractory to methotrexate, alternative to biologics.",
        "indications": [
            "Rheumatoid Arthritis (moderate-severe)",
            "Psoriatic Arthritis",
            "Ulcerative Colitis (refractory)"
        ],
        "contraindications": [
            "Active Serious Infections",
            "Severe Hepatic Impairment"
        ],
        "sideEffects": [
            "Infections (serious - TB, fungal, opportunistic)",
            "Malignancy (lymphoma, skin cancer)",
            "Thrombosis (DVT, PE, arterial - FDA black box)",
            "GI perforation",
            "Lipid elevations",
            "Cytopenias (anemia, neutropenia, lymphopenia)"
        ],
        "interactions": "Strong CYP3A4 inhibitors/inducers (alter levels), live vaccines (contraindicated), immunosuppressants (additive immunosuppression).",
        "interactionDetails": "CYP3A4 INHIBITORS: MECHANISM - Tofacitinib metabolized by CYP3A4. Inhibitors (ketoconazole, clarithromycin) increase tofacitinib levels. CONSEQUENCE - Increased immunosuppression and side effects. Reduce tofacitinib dose by 50% with strong inhibitors. CYP3A4 INDUCERS: MECHANISM - Inducers (rifampin) decrease tofacitinib levels. CONSEQUENCE - Reduced efficacy. May need dose increase or avoid concurrent use. LIVE VACCINES: MECHANISM - JAK inhibition impairs immune response. CONSEQUENCE - Risk of infection from live vaccine. Contraindicated. Update vaccines before starting therapy.",
        "pageType": "drug"
    },
    {
        "id": "anakinra",
        "name": "Anakinra",
        "pharmacologicClass": "il-1-inhibitors",
        "therapeuticClass": "rheumatoid-arthritis-medications",
        "system": "immunology-rheumatology",
        "mechanism": "Recombinant IL-1 receptor antagonist that blocks interleukin-1 alpha and beta signaling.",
        "features": "Daily subcutaneous injection, short half-life, rapid onset/offset.",
        "clinicalChoice": "RA refractory to other DMARDs, cryopyrin-associated periodic syndromes (CAPS).",
        "indications": [
            "Rheumatoid Arthritis",
            "Cryopyrin-Associated Periodic Syndromes (CAPS)",
            "Systemic Juvenile Idiopathic Arthritis"
        ],
        "contraindications": [
            "Active Infections",
            "Hypersensitivity to E. coli-derived proteins"
        ],
        "sideEffects": [
            "Injection site reactions (very common, 70%)",
            "Infections (serious)",
            "Neutropenia",
            "Headache"
        ],
        "interactions": "TNF inhibitors (increased infection risk - not recommended), live vaccines (avoid).",
        "interactionDetails": "TNF INHIBITORS: MECHANISM - Both anakinra (IL-1 blockade) and TNF inhibitors provide profound immunosuppression through different cytokine pathways. CONSEQUENCE - Significantly increased risk of serious infections without additional clinical benefit. Combination not recommended. LIVE VACCINES: MECHANISM - IL-1 is critical for immune response. Blockade impairs response to vaccines. CONSEQUENCE - Risk of infection from live vaccines. Avoid live vaccines during therapy.",
        "pageType": "drug"
    },
    {
        "id": "tocilizumab",
        "name": "Tocilizumab",
        "pharmacologicClass": "il-6-inhibitors",
        "therapeuticClass": "rheumatoid-arthritis-medications",
        "system": "immunology-rheumatology",
        "mechanism": "Monoclonal antibody against IL-6 receptor (both soluble and membrane-bound), blocking IL-6 mediated inflammation.",
        "features": "IV or subcutaneous, blocks IL-6 (key inflammatory cytokine), affects acute phase reactants (CRP, ESR).",
        "clinicalChoice": "Moderate-severe RA refractory to methotrexate or TNF inhibitors, giant cell arteritis, cytokine release syndrome.",
        "indications": [
            "Rheumatoid Arthritis (moderate-severe)",
            "Giant Cell Arteritis",
            "Systemic Juvenile Idiopathic Arthritis",
            "Cytokine Release Syndrome (CAR-T therapy)",
            "COVID-19 (severe - off-label)"
        ],
        "contraindications": [
            "Active Infections",
            "Platelet count <50,000",
            "ANC <500",
            "Diverticulitis (GI perforation risk)"
        ],
        "sideEffects": [
            "Infections (serious - TB, fungal, bacterial)",
            "GI perforation (especially with diverticulitis)",
            "Hepatotoxicity (transaminase elevations)",
            "Cytopenias (neutropenia, thrombocytopenia)",
            "Lipid elevations (total cholesterol, LDL, triglycerides)",
            "Infusion reactions"
        ],
        "interactions": "Live vaccines (avoid), CYP450 substrates (IL-6 suppression normalizes CYP activity).",
        "interactionDetails": "CYP450 SUBSTRATES: MECHANISM - IL-6 suppresses CYP450 enzymes. Tocilizumab blocks IL-6, restoring normal CYP activity and increasing metabolism of CYP substrates. CONSEQUENCE - Decreased levels of drugs metabolized by CYP450 (statins, warfarin, oral contraceptives, immunosuppressants). Monitor levels, may need dose adjustment. LIVE VACCINES: MECHANISM - IL-6 blockade impairs immune response. CONSEQUENCE - Risk of infection from live vaccines. Update vaccines before therapy.",
        "pageType": "drug"
    },
    {
        "id": "febuxostat",
        "name": "Febuxostat",
        "pharmacologicClass": "xanthine-oxidase-inhibitors",
        "therapeuticClass": "gout-medications",
        "system": "immunology-rheumatology",
        "mechanism": "Non-purine selective xanthine oxidase inhibitor that reduces uric acid production.",
        "features": "More potent than allopurinol, doesn't require renal dose adjustment (hepatic metabolism).",
        "clinicalChoice": "Chronic gout/hyperuricemia in patients with CKD or allopurinol intolerance/failure.",
        "indications": [
            "Chronic Gout",
            "Hyperuricemia",
            "Tumor Lysis Syndrome Prevention"
        ],
        "contraindications": [
            "Concurrent Azathioprine or Mercaptopurine (severe toxicity)",
            "CV disease (FDA warning - increased CV death vs allopurinol)"
        ],
        "sideEffects": [
            "Cardiovascular events (MI, stroke - FDA black box)",
            "Gout flare (early treatment - prophylax with colchicine/NSAID)",
            "Hepatotoxicity",
            "Rash (including Stevens-Johnson syndrome)",
            "Nausea"
        ],
        "interactions": "Azathioprine/mercaptopurine (CONTRAINDICATED - severe myelosuppression), theophylline (increased levels).",
        "interactionDetails": "AZATHIOPRINE/MERCAPTOPURINE: MECHANISM - These prodrugs are metabolized by xanthine oxidase to inactive metabolites. Febuxostat blocks this metabolism. CONSEQUENCE - Severe, potentially fatal bone marrow suppression. Absolute contraindication. THEOPHYLLINE: MECHANISM - Theophylline is metabolized by xanthine oxidase. Febuxostat inhibition increases theophylline levels. CONSEQUENCE - Theophylline toxicity (seizures, arrhythmias). Monitor levels, reduce theophylline dose.",
        "pageType": "drug"
    }

];export default drugs;
